Dendritic cell-based immunotherapy for malignant gliomas

References

• Legler JM, Ries LA, Smith MA et al. Cancer surveillance series (corrected): brain and other central nervous system cancers: recent trends in incidence and mortality. J. Natl Cancer Inst. 91, 1382–1390 (1999).
   PubMed Web of Science ®Google Scholar
• Surawicz TS, Davis F, Freels S, Laws ER Jr, Menck HR. Brain tumor survival: results from the National Cancer Data Base. J. Neurooncol. 40, 151–160 (1998).
   PubMed Web of Science ®Google Scholar
• Ehtesham M, Samoto K, Kabos P et al. Treatment of intracranial glioma with in situ interferon-γ and tumor necrosis factor-α gene transfer. Cancer Gene Ther. 9, 925–934 (2002).
   PubMed Web of Science ®Google Scholar
• Liau LM, Black KL, Prins RM et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J. Neurosurg. 90, 1115–1124 (1999).
   PubMed Web of Science ®Google Scholar
• Liu Y, Ehtesham M, Samoto K et al. In situ adenoviral interleukin-12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. Cancer Gene Ther. 9, 9–15 (2002).
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Kramm CM, Johnston KM et al. Vaccination for experimental gliomas using GM–CSF-transduced glioma cells. Cancer Gene Ther. 4, 345–352 (1997).
   PubMed Web of Science ®Google Scholar
• Cserr HF, Knopf PM. Cervical lymphatics, the blood–brain barrier and the immunoreactivity of the brain: a new view. Immunol. Today 13, 507–512 (1992).
   PubMedGoogle Scholar
• Becher B, Prat A, Antel JP. Brain–immune connection: immuno-regulatory properties of CNS-resident cells. Glia 29, 293–304 (2000).
   PubMed Web of Science ®Google Scholar
• Hickey WF. Leukocyte traffic in the central nervous system: the participants and their roles. Semin. Immunol.11, 125–137 (1999).
   PubMed Web of Science ®Google Scholar
• Anderson AC, Nicholson LB, Legge KL, Turchin V, Zaghouani H, Kuchroo VK. High frequency of autoreactive myelin proteolipid protein-specific T-cells in the periphery of naive mice: mechanisms of selection of the self-reactive repertoire. J. Exp. Med. 191, 761–770 (2000).
   PubMedGoogle Scholar
• Stohlman SA, Hinton DR. Viral induced demyelination. Brain Pathol. 11, 92–106 (2001).
   PubMedGoogle Scholar
• Kuchroo VK, Anderson AC, Waldner H, Munder M, Bettelli, E, Nicholson LB. T-cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T-cell repertoire. Ann. Rev. Immunol. 20, 101–123 (2002).
   PubMed Web of Science ®Google Scholar
• Adorini L. Immunotherapeutic approaches in multiple sclerosis. J. Neurol. Sci. 223, 13–24 (2004).
   Google Scholar
• Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-β in Lewis rats. J. Neuroimmunol. 156, 3–9 (2004).
   PubMed Web of Science ®Google Scholar
• Qing Z, Sewell D, Sandor M, Fabry Z. Antigen-specific T-cell trafficking into the central nervous system. J. Neuroimmunol. 105, 169–178 (2000).
   Google Scholar
• Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA Jr. Surface expression of α4 integrin by CD4 T-cells is required for their entry into brain parenchyma. J. Exp. Med. 177, 57–68, 1993.
   Google Scholar
• Ford AL, Foulcher E, Lemckert FA, Sedgwick JD. Microglia induce CD4 T lymphocyte final effector function and death. J. Exp. Med. 184, 1737–1745 (1996).
   PubMed Web of Science ®Google Scholar
• Irani DN. Brain-derived gangliosides induce cell cycle arrest in a murine T-cell line. J. Neuroimmunol.87, 11–16 (1998).
   Google Scholar
• Wilbanks GA Streilein JW. Fluids from immune privileged sites endow macrophages with the capacity to induce antigen-specific immune deviation via a mechanism involving transforming growth factor-β. Eur. J. Immunol. 22, 1031–1036 (1992).
   PubMedGoogle Scholar
• Suvannavejh GC, Dal Canto MC, Matis LA, Miller SD. Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis. J. Clin. Invest. 105, 223–231 (2000).
   PubMed Web of Science ®Google Scholar
• Bauer J, Bradl M, Hickley WF et al. T-cell apoptosis in inflammatory brain lesions: destruction of T-cells does not depend on antigen recognition. Am. J. Pathol. 153, 715–724 (1998).
   Google Scholar
• Benveniste EN. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J. Mol. Med.75, 165–173 (1997).
   PubMed Web of Science ®Google Scholar
• Merrill JE, Murphy SP. Inflammatory events at the blood brain barrier: regulation of adhesion molecules, cytokines, and chemokines by reactive nitrogen and oxygen species. Brain Behav. Immun. 11, 245–263 (1997).
   PubMed Web of Science ®Google Scholar
  Mekala DJ, Geiger TL. Immunotherapy of autoimmune encephalomyelitis with re-directed CD4+CD25+ T-lymphocytes. Blood 105(5), 2090–2092 (2005).
   Google Scholar
• Gordon LB, Nolan SC, Cserr HF, Knopf PM, Harling-Berg CJ. Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: a new tumor model for regional central nervous system immunity. J. Immunol. 159, 2399–2408 (1997).
   PubMed Web of Science ®Google Scholar
• Walker PR, Calzascia T, Schnuriger V et al. The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T-cells. J. Immunol. 165, 3128–3135 (2000).
   PubMed Web of Science ®Google Scholar
• Graeber MB, Scheithauer BW, Kreutzberg GW. Microglia in brain tumors. Glia 40, 252–259 (2002).
   PubMed Web of Science ®Google Scholar
• Schneider J, Hofman FM, Apuzzo ML, Hinton DR. Cytokines and immunoregulatory molecules in malignant glial neoplasms. J. Neurosurg. 77, 265–273 (1992).
   PubMed Web of Science ®Google Scholar
• Fischer HG, Reichmann G. Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J. Immunol. 166, 2717–2726 (2001).
   PubMed Web of Science ®Google Scholar
• Yang T, Witham TF, Villa L et al. Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas. Cancer Res. 62, 2583–2591 (2002).
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392, 245–252 (1998).
   PubMed Web of Science ®Google Scholar
• Gunzer M, Janich S, Varga G, Grabbe S. Dendritic cells and tumor immunity. Semin. Immunol. 13, 291–302 (2001).
   PubMed Web of Science ®Google Scholar
• Hart MN, Fabry Z. CNS antigen presentation. Trends Neurosci. 18, 475–481 (1995).
   Google Scholar
• Ehtesham M, Kabos P, Gutierrez MA, Samoto K, Black KL, Yu JS. Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats. J. Immunother. 26, 107–116 (2003).
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Akasaki Y, Abe T, Ohno T. Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model. Cancer Immunol. Immunother. 51, 424–430 (2002).
   PubMed Web of Science ®Google Scholar
• Imaizumi T, Kuramoto T, Matsunaga K et al. Expression of the tumor-rejection antigen SART1 in brain tumors. Int. J. Cancer 83, 760–764 (1999).
   PubMed Web of Science ®Google Scholar
• Murayama K, Kobayashi T, Imaizumi T et al. Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides. J. Immunother. 23, 511–518 (2000).
   PubMed Web of Science ®Google Scholar
• Nonaka Y, Tsuda N, Shichijo S et al. Recognition of ADP-ribosylation factor 4-like by HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes from patients with brain tumors. Tissue Antigens 60, 319–327 (2002).
   Google Scholar
• Tsuda N, Nonaka Y, Shichijo S et al. UDP-Gal: βGlcNAc β1, 3-galactosyltransferase, polypeptide 3 (GALT3) is a tumour antigen recognised by HLA-A2-restricted cytotoxic T-lymphocytes from patients with brain tumour. Br. J. Cancer 87, 1006–1012 (2002).
   Google Scholar
• Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H. Identification of a novel HLA-A*0201-restricted, cytotoxic T-lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor α2 chain. Clin. Cancer Res. 8, 2851–2855 (2002).
   PubMed Web of Science ®Google Scholar
• Liu G, Khong HT, Wheeler CJ, Yu JS, Black KL, Ying H. Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T-lymphocyte target in patients with malignant glioma. J. Immunother. 26, 301–312 (2003).
   PubMed Web of Science ®Google Scholar
• Liu G, Yu JS, Zeng G et al. AIM-2: a novel tumor antigen is expressed and presented by human glioma cells. J. Immunother. 27, 220–226 (2004).
   PubMed Web of Science ®Google Scholar
• Liu G, Ying H, Zeng G, Wheeler CJ, Black KL, Yu JS. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T-cells. Cancer Res. 64, 4980–4986 (2004).
   PubMed Web of Science ®Google Scholar
• Pardoll D. Does the immune system see tumors as foreign or self? Ann. Rev. Immunol. 21, 807–839 (2003).
   PubMed Web of Science ®Google Scholar
• Tacconi L, Stapleton S, Signorelli F, Thomas DG. Acquired immune deficiency syndrome (AIDS) and cerebral astrocytoma. Clin. Neurol. Neurosurg. 98, 149–151 (1996).
   Google Scholar
• Wolff R, Zimmermann M, Marquardt G, Lanfermann H, Nafe R, Seifert V. Glioblastoma multiforme of the brain stem in a patient with acquired immunodeficiency syndrome. Acta Neurochir. (Wien) 144, 941–945 (2002).
   Google Scholar
• Salvati M, Frati A, Caroli E et al. Glioblastoma in kidney transplant recipients. Report of five cases. J. Neurooncol. 63, 33–37 (2003).
   Google Scholar
• Fenstermaker RA, Ciesielski MJ. Immunotherapeutic strategies for malignant glioma. Cancer Control 11, 181–191 (2004).
   Google Scholar
• Yang L, Ng KY, Lillehei KO. Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. Cancer Control 10, 138–147 (2003).
   PubMedGoogle Scholar
• Ehtesham M, Black KL, Yu JS. Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials. Cancer Control 11, 192–207 (2004).
   PubMedGoogle Scholar
• Zou JP, Morford LA, Chougnet C et al. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J. Immunol. 162, 4882–4892 (1999).
   PubMed Web of Science ®Google Scholar
• Roszman T, Elliott L, Brooks W. Modulation of T-cell function by gliomas. Immunol. Today 12, 370–374 (1991).
   PubMedGoogle Scholar
• Weller M, Fontana A. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β, T-cell apoptosis, and the immune privilege of the brain. Brain Res. Rev. 21, 128–151 (1995).
   PubMed Web of Science ®Google Scholar
• Akasaki Y, Liu G, Chung NH, Ehtesham M, Black KL, Yu JS. Induction of a CD4+ T regulatory Type 1 response by cyclooxygenase-2-overexpressing glioma. J. Immunol. 173, 4352–4359 (2004).
   PubMed Web of Science ®Google Scholar
• Chaux P, Favre N, Bonnotte B, Moutet M, Martin M, Martin F. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression. A role in the immune tolerance to antigenic tumors. Adv. Exp. Med. Biol. 417, 525–528 (1997).
   PubMedGoogle Scholar
• Chaux P, Favre N, Martin M, Martin F. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int. J. Cancer 72, 619–624 (1997).
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res. 3, 483–490 (1997).
   PubMed Web of Science ®Google Scholar
• Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin. Cancer Res.4, 585–593 (1998).
   PubMed Web of Science ®Google Scholar
• Yu JS, Wheeler CJ, Zeltzer PM et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 61, 842–847 (2001).
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Yajima N, Abe T et al. Dendritic cell-based glioma immunotherapy (review). Int. J. Oncol. 23, 5–15 (2003).
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, Ohno T. Results of a Phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother. 50, 337–344 (2001).
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Abe T, Ohno T. Effects of glioma cells on maturation of dendritic cells. J. Neurooncol. 58, 125–130 (2002).
   Google Scholar
• Yu JS, Lee PK, Ehtesham M, Samoto K, Black KL, Wheeler CJ. Intratumoral T-cell subset ratios and Fas ligand expression on brain tumor endothelium. J. Neurooncol. 64, 55–61 (2003).
   PubMed Web of Science ®Google Scholar
• Wintterle S, Schreiner B, Mitsdoerffer M et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res.63, 7462–7467 (2003).
   PubMed Web of Science ®Google Scholar
• Wiendl H, Mitsdoerffer M, Hofmeister V et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J. Immunol. 168, 4772–4780 (2002).
   PubMed Web of Science ®Google Scholar
• Huettner C, Paulus W, Roggendorf W. Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am. J. Pathol. 146, 317–322 (1995).
   PubMed Web of Science ®Google Scholar
• Harada M, Matsunaga K, Oguchi Y et al. The involvement of transforming growth factor β in the impaired antitumor T-cell response at the gut-associated lymphoid tissue (GALT). Cancer Res. 55, 6146–6151 (1995).
   PubMed Web of Science ®Google Scholar
• Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T-regulatory cells. Immunol. Rev. 182, 68–79 (2001).
   PubMed Web of Science ®Google Scholar
• Groux H, O'Garra A, Bigler M et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389, 737–742 (1997).
   PubMed Web of Science ®Google Scholar
• Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T-cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265, 1237–1240 (1994).
   PubMed Web of Science ®Google Scholar
• Inobe J, Slavin AJ, Komagata Y, Chen Y, Liu L, Weiner HL. IL-4 is a differentiation factor for transforming growth factor-β secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis. Eur. J. Immunol. 28, 2780–2790 (1998).
   PubMed Web of Science ®Google Scholar
• Levings MK, Sangregorio R, Sartirana C et al. Human CD25+CD4+ T suppressor cell clones produce transforming growth factor β, but not interleukin 10, and are distinct from type 1 T regulatory cells. J. Exp. Med. 196, 1335–1346 (2002).
   PubMed Web of Science ®Google Scholar
• Albert ML, Jegathesan M, Darnell RB. Dendritic cell maturation is required for the cross-tolerization of CD8+ T-cells. Nature Immunol. 2, 1010–1017 (2001).
   Google Scholar
• Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med. 191, 411–416 (2000).
   PubMed Web of Science ®Google Scholar
• Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Ann. Rev. Immunol. 21, 685–711 (2003).
   PubMed Web of Science ®Google Scholar
• Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med. 191, 423–434 (2000).
   PubMed Web of Science ®Google Scholar
• Mahnke K, Schmitt E, Bonifaz L, Enk AH, Jonuleit H. Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunol. Cell. Biol. 80, 477–483 (2002).
   PubMed Web of Science ®Google Scholar
• Yamazaki S, Iyoda T, Tarbell K et al. Direct expansion of functional CD25+ CD4+ regulatory T-cells by antigen-processing dendritic cells. J. Exp. Med. 198, 235–247 (2003).
   PubMed Web of Science ®Google Scholar
• Harizi H, Juzan M, Pitard V, Moreau JF, Gualde N. Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J. Immunol. 168, 2255–2263 (2002).
   PubMed Web of Science ®Google Scholar
• Leslie CC. Properties and regulation of cytosolic phospholipase A2. J. Biol. Chem. 272, 16709–16712 (1997).
   PubMed Web of Science ®Google Scholar
• Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 61, 4375–4381 (2001).
   PubMed Web of Science ®Google Scholar
• Joki T, Heese O, Nikas DC et al. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res. 60, 4926–4931 (2000).
   PubMed Web of Science ®Google Scholar
• Dix AR, Brooks WH, Roszman TL, Morford LA. Immune defects observed in patients with primary malignant brain tumors. J. Neuroimmunol. 100, 216–232 (1999).
   PubMed Web of Science ®Google Scholar
• Dermime S, Armstrong A, Hawkins RE, Stern PL. Cancer vaccines and immunotherapy. Br. Med. Bull. 62, 149–162 (2002).
   PubMed Web of Science ®Google Scholar
• Holladay FP, Heitz T, Wood GW. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T-lymphocytes, but not by lymphokine-activated killer cells. J. Neurosurg.77, 757–762 (1992).
   PubMed Web of Science ®Google Scholar
• Okada H, Pollack IF. Cytokine gene therapy for malignant glioma. Expert Opin. Biol. Ther. 4, 1609–1620 (2004).
   PubMed Web of Science ®Google Scholar
• Fong L, Engleman G. Dendritic cells in cancer immunotherapy. Ann. Rev. Immunol. 18, 245–273 (2000).
   PubMed Web of Science ®Google Scholar
• Yu JS, Burwick JA, Dranoff G, Breakefield XO. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum. Gene Ther. 8, 1065–1072 (1997).
   PubMed Web of Science ®Google Scholar
• Sobol RE, Fakhrai H, Shawler D et al. Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther. 2, 164–167 (1995).
   PubMed Web of Science ®Google Scholar
• Joki T, Kikuchi T, Akasaki Y, Saitoh S, Abe T, Ohno T. Induction of effective antitumor immunity in a mouse brain tumor model using B7–1 (CD80) and intercellular adhesive molecule 1 (ICAM-1; CD54) transfection and recombinant interleukin 12. Int. J. Cancer 82, 714–720 (1999).
   PubMed Web of Science ®Google Scholar
• Soos JM, Krieger JI, Stuve O et al. Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFNγ-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4+ T-cell activation. Glia 36, 391–405, (2001).
   Google Scholar
• Heimberger AB, Crotty LE, Archer GE et al. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J. Neuroimmunol. 103, 16–25 (2000).
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Zullo SA, Tanaka R, Blaese M, Xanthopoulos KG. Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA. J. Neurosurg. 94, 474–481 (2001).
   PubMed Web of Science ®Google Scholar
• Akasaki Y, Kikuchi T, Homma S, Abe T, Kofe D, Ohno T. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J. Immunother. 24, 106–113 (2001).
   Web of Science ®Google Scholar
• Witham TF, Erff ML, Okada H, Chambers WH, Pollack IF. 7-hydroxystaurosporine-induced apoptosis in 9L glioma cells provides an effective antigen source for dendritic cells and yields a potent vaccine strategy in an intracranial glioma model. Neurosurgery 50, 1327–1335 (2002).
   Google Scholar
• Yamanaka R, Yajima N, Tsuchiya N et al. Administration of interleukin-12 and -18 enhancing the antitumor immunity of genetically modified dendritic cells that had been pulsed with Semliki forest virus-mediated tumor complementary DNA. J. Neurosurg. 97, 1184–1190 (2002).
   PubMed Web of Science ®Google Scholar
• Saito R, Mizuno M, Nakahara N et al. Vaccination with tumor cell lysate-pulsed dendritic cells augments the effect of IFN-β gene therapy for malignant glioma in an experimental mouse intracranial glioma. Int. J. Cancer 111, 777–782, (2004).
   PubMed Web of Science ®Google Scholar
• Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med. 1, 1297–1302 (1995).
   PubMed Web of Science ®Google Scholar
• Soling A, Rainov NG. Dendritic cell therapy of primary brain tumors. Mol. Med. 7, 659–667 (2001).
   Google Scholar
• Fecci PE, Mitchell DA, Archer GE et al. The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. J. Neurooncol. 64, 161–176 (2003).
   PubMed Web of Science ®Google Scholar
• Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T-cells in the antitumor immune response. J. Exp. Med. 188, 2357–2368 (1998).
   PubMed Web of Science ®Google Scholar
• Bourgeois C, Rocha B, Tanchot C. A role for CD40 expression on CD8+ T-cells in the generation of CD8+ T-cell memory. Science 297, 2060–2063 (2002).
   PubMed Web of Science ®Google Scholar
• Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393, 478–480 (1998).
   PubMed Web of Science ®Google Scholar
• Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393, 474–478 (1998).
   PubMed Web of Science ®Google Scholar
• Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T-lymphocytes is mediated by CD40–CD40L interactions. Nature 393, 480–483 (1998).
   PubMed Web of Science ®Google Scholar
• Tatsumi T, Kierstead LS, Ranieri E et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T-cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J. Exp. Med. 196, 619–628 (2002).
   PubMed Web of Science ®Google Scholar
• Slager EH, Borghi, M, van der Minne CE et al. CD4+ Th2 cell recognition of HLA-DR-restricted epitopes derived from CAMEL: a tumor antigen translated in an alternative open reading frame. J. Immunol. 170, 1490–1497 (2003).
   Google Scholar
• Gately MK, Renzetti LM, Magram J et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Ann. Rev. Immunol. 16, 495–521 (1998).
   PubMed Web of Science ®Google Scholar
• Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Ann. Rev. Immunol. 19, 423–474 (2001).
   PubMed Web of Science ®Google Scholar
• Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T-cell responses. Immunity 19, 641–644 (2003).
   PubMed Web of Science ®Google Scholar
• Lankford CS, Frucht DM. A unique role for IL-23 in promoting cellular immunity. J. Leukoc. Biol. 73, 49–56 (2003).
   PubMed Web of Science ®Google Scholar
• Pirhonen J, Matikainen S, Julkunen I. Regulation of virus-induced IL-12 and IL-23 expression in human macrophages. J. Immunol. 169, 5673–5678 (2002).
   PubMed Web of Science ®Google Scholar
• Belladonna ML, Renauld JC, Bianchi R et al. IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J. Immunol. 168, 5448–5454 (2002).
   PubMed Web of Science ®Google Scholar
• Liu G, Ng H, Akasaki Y et al. Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response. Eur. J. Immunol. 34, 1680–1687 (2004).
   PubMed Web of Science ®Google Scholar
• Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Ann. Rev. Immunol. 19, 683–765 (2001).
   PubMed Web of Science ®Google Scholar
• Kawashima I, Hudson SJ, Tsai V et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum. Immunol. 59, 1–14 (1998).
   PubMed Web of Science ®Google Scholar
• Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nature Biotechnol. 16, 364–369 (1998).
   PubMed Web of Science ®Google Scholar
• Jingwu Z, Medaer R, Hashim GA, Chin Y, van den Berg-Loonen E, Raus JC. Myelin basic protein-specific T lymphocytes in multiple sclerosis and controls: precursor frequency, fine specificity, and cytotoxicity. Ann. Neurol.32, 330–338 (1992).
   PubMed Web of Science ®Google Scholar
• Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 64, 4973–4979 (2004).
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Akasaki Y, Abe T et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J. Immunother. 27, 452–459 (2004).
   PubMed Web of Science ®Google Scholar
• Inaba K, Inaba M, Naito M, Steinman RM. Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo. J. Exp. Med. 178, 479–488 (1993).
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Abe T, Yajima N et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical Phase I/II trial. Br. J. Cancer 89, 1172–1179 (2003).
   PubMed Web of Science ®Google Scholar
• Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin. Cancer Res. 10, 5316–5326 (2004).
   PubMed Web of Science ®Google Scholar
• Chu W, Pak BJ, Bani MR et al. Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications. Oncogene 19, 395–402 (2000).
   PubMed Web of Science ®Google Scholar
• Liu G, Akasaki Y, Khong HT et al. Cytotoxic T-cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene (2005) (In Press).
   Google Scholar